keyword
MENU ▼
Read by QxMD icon Read
search

rheumatologic emergencies

keyword
https://www.readbyqxmd.com/read/29442540/management-of-immune-related-adverse-events-in-patients-treated-with-immune-checkpoint-inhibitor-therapy-american-society-of-clinical-oncology-clinical-practice-guideline
#1
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B Leighl, Jennifer S Mammen, David F McDermott, Aung Naing, Loretta J Nastoupil, Tanyanika Phillips, Laura D Porter, Igor Puzanov, Cristina A Reichner, Bianca D Santomasso, Carole Seigel, Alexander Spira, Maria E Suarez-Almazor, Yinghong Wang, Jeffrey S Weber, Jedd D Wolchok, John A Thompson
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process...
February 14, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29439289/switching-from-reference-adalimumab-to-sb5-adalimumab-biosimilar-in-patients-with-rheumatoid-arthritis-52-week-phase-3-randomized-study-results
#2
Michael E Weinblatt, Asta Baranauskaite, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz-Rosiak, Inyoung Baek, Jeehoon Ghil
OBJECTIVES: The 24-week equivalent efficacy and comparable safety results of SB5 and reference adalimumab (ADA) from the phase 3 randomized study in patients with moderate to severe rheumatoid arthritis (RA) have been reported previously. This transition study evaluated patients who switched from ADA to SB5 or continued on SB5 or ADA up to 52 weeks. METHODS: In this phase 3 study, patients were initially randomized 1:1 to receive SB5 or ADA (40 mg subcutaneously every other week)...
February 13, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29438606/experience-and-context-shape-patient-and-clinician-goals-for-treatment-of-rheumatoid-arthritis-a-qualitative-study
#3
Jennifer L Barton, Elizabeth Hulen, Allison Schue, Edward H Yelin, Sarah S Ono, Anais Tuepker, Christopher J Koenig
OBJECTIVE: Patient and clinician goal alignment, central to effective patient-centered care, has been linked to improved patient experience and outcomes, but has not been explored in rheumatoid arthritis (RA). This study aimed to explore goal conceptualization among RA patients and clinicians. METHODS: Seven focus groups and one semi-structured interview were conducted with RA patients and clinicians recruited from four rheumatology clinics. An interview guide was developed to explore goal concordance related to RA treatment...
February 13, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/29346193/perceptions-of-infection-risk-with-immunomodulatory-medications
#4
Rebecca Sharim, Preethi Thomas, Leny Mathew, Michael George, Misha Rosenbach
OBJECTIVES: Physicians of many specialties encounter patients treated with immunomodulatory medications and must weigh the risk of infection when making medical decisions. We explored how physician perceptions of the infection risk of immunomodulatory medications differ by specialty and level of experience. METHODS: A survey was distributed to physicians from the internal medicine, family medicine, emergency medicine, rheumatology, dermatology, and infectious disease departments at 1 tertiary care institution...
January 9, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29336187/efficacy-and-safety-of-sirukumab-in-japanese-patients-with-moderate-to-severe-rheumatoid-arthritis-inadequately-controlled-by-disease-modifying-anti-rheumatic-drugs-subgroup-analysis-of-a-phase-3-study
#5
Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Masayoshi Harigai, Toshikazu Nakano, Koshiro Akagi, Yoshifumi Ukyo, Benjamin Hsu
Objective To evaluate the efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis uncontrolled by disease modifying antirheumatic drugs. Methods This subgroup analysis based on a double-blind, placebo-controlled, 52-week phase 3 study (SIRROUND-D) assessed American College of Rheumatology (ACR)20 response at week 16 and van der Heijde-modified Sharp score (vdH-S) at week 52 (coprimary endpoints). Results A total of 168 (Japanese)/1670 patients received sirukumab 50 mg/4 weeks (q4w, n = 58), 100 mg/every 2 weeks (q2w, n = 54), or placebo (n = 56) subcutaneously...
January 16, 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/29323836/segmental-arterial-mediolysis-an-unusual-case-mistaken-to-be-a-strangulated-hernia
#6
Russell D Japikse, James E Sevenson, Perry J Pickhardt, Michael D Repplinger
INTRODUCTION: Segmental arterial mediolysis (SAM) is a rare nonatherosclerotic, noninflammatory vasculopathy causing arterial wall necrosis that leads to strictures, dissections, and aneurysms, particularly in medium-sized abdominal arteries. Awareness of SAM is important because, unlike vasculitides, immunosuppressive treatment may worsen the disease process. CASE: A 58-year-old man with multiple medical comorbidities presented with acute epigastric pain and a right incarcerated inguinal hernia that was interpreted as showing bowel strangulation on computed tomography...
August 2017: WMJ: Official Publication of the State Medical Society of Wisconsin
https://www.readbyqxmd.com/read/29303700/the-eumusc-net-standards-of-care-for-rheumatoid-arthritis-importance-and-current-implementation-according-to-patients-and-healthcare-providers-in-the-netherlands
#7
Monika Hifinger, Sofia Ramiro, Polina Putrik, Yvonne van Eijk-Hustings, Anthony Woolf, Josef S Smolen, Michaela Stoffer-Marx, Tillman Uhlig, Rikke Helene Moe, Merdan Saritas, Marian Janson, Annette van der Helm-van Mil, Mart van de Laar, Harald Vonkeman, Maarten de Wit, Annelies Boonen
OBJECTIVES: The eumusc.net standards of care (SOCs) for rheumatoid arthritis (RA) aimed to improve quality of care across Europe. This study investigated importance and implementation of each standard according to patients and health care professionals (HCPs) in the Netherlands and identified barriers towards implementation. METHODS: Dutch patients, rheumatologists and rheumatology nurses rated importance and implementation (0-10 numeric rating scale (NRS); 10=most important/best implemented) for each of the 20 SOCs...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29275332/dual-il-17a-and-il-17f-neutralisation-by-bimekizumab-in-psoriatic-arthritis-evidence-from-preclinical-experiments-and-a-randomised-placebo-controlled-clinical-trial-that-il-17f-contributes-to-human-chronic-tissue-inflammation
#8
Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Alastair D G Lawson, Ash Maroof, Ruth Oliver, Serghei Popa, Foteini Strimenopoulou, Pavan Vajjah, Mark I L Watling, Nataliya Yeremenko, Pierre Miossec, Stevan Shaw
OBJECTIVE: Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear. We hypothesised that IL-17F, together with IL-17A, contributes to chronic tissue inflammation, and that dual neutralisation may lead to more profound suppression of inflammation than inhibition of IL-17A alone. METHODS: Preclinical experiments assessed the role of IL-17A and IL-17F in tissue inflammation using disease-relevant human cells...
December 23, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29247148/efficacy-and-safety-of-ixekizumab-in-patients-with-active-psoriatic-arthritis-52-week-results-from-a-phase-iii-study-spirit-p1
#9
Désirée van der Heijde, Dafna D Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S Rathmann, Susan R Moriarty, Catherine L Shuler, Hilde Carlier, Olivier Benichou, Philip J Mease
OBJECTIVE: To evaluate the efficacy and safety of ixekizumab (IXE), an interleukin 17A antagonist, in patients with psoriatic arthritis (PsA) after 52 weeks in a phase III study. METHODS: Patients were initially randomly assigned to IXE 80 mg every 2 weeks (IXEQ2W) or every 4 weeks (IXEQ4W) after a 160-mg starting dose, placebo (PBO), or adalimumab (ADA) 40 mg Q2W. At Week 24 (Week 16 for inadequate responders), ADA (8-week washout before starting IXE) and PBO patients were rerandomized to IXEQ2W or IXEQ4W...
December 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29232941/korean-rheumatology-workforce-from-1992-to-2015-current-status-and-future-demand
#10
Chan Uk Lee, Ji Na Kim, Ji-Won Kim, Sung-Hoon Park, Hwajeong Lee, Seong-Kyu Kim, Jung-Yoon Choe
Background/Aims: Rheumatology in Korea has rapidly advanced in the 24 years since the subspecialty board certification program was established in 1992. The objective of this investigation was to analyze the distribution of rheumatology practices in Korea in order to better understand the rheumatology workforce. Methods: Using a membership list from the Korean College of Rheumatology (KCR), we obtained information on practicing rheumatologists. We mapped the ratio of rheumatologists to the general population and to patients with rheumatologic disease using data from Statistics Korea and the 2015 Health Insurance Review & Assessment Service (HIRA)...
December 15, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29221603/emerging-therapies-for-pre-ra
#11
REVIEW
Andrew P Cope
The field of rheumatology has made major contributions to medicine through the identification of cellular and molecular targets and the development of therapies for the treatment of an impressive range of immune-mediated inflammatory diseases such as rheumatoid arthritis. In recent years, new milestones have been achieved. These include the recognition of an at-risk state, characterized by disease specific autoantibodies in serum and inflammatory joint pain, and the initiation of studies seeking to prevent high-risk individuals from progressing to a state of clinically apparent arthritis...
February 2017: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/29209946/usability-and-patient-preference-phase-3-study-of-the-sarilumab-pen-in-patients-with-active-moderate-to-severe-rheumatoid-arthritis
#12
Alan Kivitz, Lydie Baret-Cormel, Hubert van Hoogstraten, Sheldon Wang, Janie Parrino, Christine Xu, Marina Stanislav
INTRODUCTION: Sarilumab is a human monoclonal antibody that blocks the interleukin-6 receptor alpha (IL-6Rα). The phase 3 SARIL-RA-EASY study (EASY) assessed the robustness of an autoinjector (pen) for administering sarilumab when used by adults with active moderate-to-severe rheumatoid arthritis (RA) who are candidates for anti-IL-6R therapy in an unsupervised real-world setting. METHODS: EASY was a 12-week, multicenter, randomized, open-label, parallel-group usability study of the sarilumab pen and prefilled syringe...
December 5, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29185062/early-recognition-and-treatment-heralds-optimal-outcomes-the-benefits-of-combined-rheumatology-dermatology-clinics-and-integrative-care-of-psoriasis-and-psoriatic-arthritis-patients
#13
REVIEW
Teo Soleymani, Soumya M Reddy, Jeffrey M Cohen, Andrea L Neimann
PURPOSE OF REVIEW: Diagnosis and treatment of psoriatic arthritis (PsA) can be challenging and require a multidisciplinary approach. This review provides an overview of combined dermatology-rheumatology clinics. RECENT FINDINGS: Combined dermatology-rheumatology clinics have emerged to optimize integrated care for patients with psoriasis and PsA. There are over 20 such clinics across the USA. These clinics facilitate multidisciplinary care for patients with psoriasis and PsA and have been found to improve outcomes and enhance both patient and physician satisfaction and knowledge...
November 20, 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29181551/-metabolic-disorders-as-paraneoplastic-syndromes
#14
REVIEW
S Krug, P Michl
Paraneoplastic syndromes are characterized by the tumor-induced release of peptide hormones and/or the initiation of immune phenomena, which elicit clinical changes and alterations in laboratory parameters independent of the tumor size and spread. In addition to neurological, endocrinal and rheumatological phenotypes, metabolic alterations play a special role in the clinical routine as they commonly present with acute symptoms in an emergency situation and necessitate immediate diagnosis and prompt initiation of treatment...
November 27, 2017: Der Internist
https://www.readbyqxmd.com/read/29181334/inflammatory-signaling-pathways-in-preleukemic-and-leukemic-stem-cells
#15
REVIEW
Shayda Hemmati, Tamanna Haque, Kira Gritsman
Hematopoietic stem cells (HSCs) are a rare subset of bone marrow cells that usually exist in a quiescent state, only entering the cell cycle to replenish the blood compartment, thereby limiting the potential for errors in replication. Inflammatory signals that are released in response to environmental stressors, such as infection, trigger active cycling of HSCs. These inflammatory signals can also directly induce HSCs to release cytokines into the bone marrow environment, promoting myeloid differentiation. After stress myelopoiesis is triggered, HSCs require intracellular signaling programs to deactivate this response and return to steady state...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29127246/non-oncologic-applications-of-pet-ct-and-pet-mr-in-musculoskeletal-orthopedic-and-rheumatologic-imaging-general-considerations-techniques-and-radiopharmaceuticals
#16
Ali Gholamrezanezhad, Kyle Basques, Ali Batouli, Mojtaba Olyaie, George Matcuk, Abass Alavi, Hossein Jadvar
Positron Emission Tomography (PET) is often underutilized in the field of musculoskeletal imaging, with key reasons including the excellent performance of conventional musculoskeletal MRI, the limited spatial resolution of PET, and the lack of reimbursement for PET for non-oncologic musculoskeletal indications. However, with improvements in PET/CT and PET/MR imaging over the last decade as well as an increased understanding of the pathophysiology of musculoskeletal diseases, there is an emerging potential for PET as a primary or complementary modality in the management of rheumatologic and orthopedic patients...
November 10, 2017: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/29116003/protocols-on-classification-monitoring-and-therapy-in-children-s-rheumatology-pro-kind-results-of-the-working-group-polyarticular-juvenile-idiopathic-arthritis
#17
REVIEW
Gerd Horneff, Ariane Klein, Gerd Ganser, Michaela Sailer-Höck, Annette Günther, Ivan Foeldvari, Frank Weller-Heinemann
OBJECTIVE: Several effective pharmacologic treatment options for polyarticual juvenile idiopathic arthritis (JIA) have emerged but initial treatment is heterogeneous in Germany. Therefore, the German Society of Pediatric Rheumatolgy has established a commission to develop consensus "Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND)" to harmonize diagnostic and treatment approaches for new-onset JIA in Germany. METHODS: A set of definitions for in- and exclusion, diagnostic workup, parameters for the evaluation of disease activity criteria, therapeutic options, medication dosing, monitoring recommendations, targets, definitions of a therapy failure and four therapeutic algorithms developed by a working group were agreed by web based survey to which all members of the GKJR have been invited...
November 7, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/29082050/a-case-of-rituximab-induced-necrotizing-fasciitis-and-a-review-of-the-literature
#18
Abdullateef Abdulkareem, Ryan S D'Souza, Oluwaseun Shogbesan, Anthony Donato
Necrotizing fasciitis is a fulminant soft tissue infection characterized by rapid progression and high mortality. Rituximab is a generally well-tolerated immunosuppresive medication used for B-cell malignancies and some rheumatological disorders. We report a case of a 69-year-old male with chronic lymphocytic leukemia who suffered necrotizing fasciitis of his left lower extremity secondary to Clostridium septicum 7 weeks after treatment with rituximab. Despite immediate intravenous antimicrobial therapy and emergent fasciotomy with extensive debridement, his hospital course was complicated by septic shock and he required an above-the-knee amputation...
2017: Case Reports in Hematology
https://www.readbyqxmd.com/read/29075504/recipients-and-providers-perspectives-of-obesity-and-potential-barriers-to-weight-management-programmes-in-patients-with-rheumatoid-arthritis-ra-a-qualitative-study
#19
G Colligan, J Galloway, H Lempp
BACKGROUND: The UK rheumatology community serves an ageing and ethnically diverse population, with a growing public health concern about obesity. Overweight and obesity contribute to 2.8 million preventable deaths annually. A raised Body Mass Index (BMI) in those with Rheumatoid Arthritis (RA) can have a significant negative impact on clinical outcomes. The aim of the study was to examine patients' and providers' perceptions of obesity and potential barriers to participation in a future weight management programme to contribute to an appropriate intervention design...
2017: BMC Obesity
https://www.readbyqxmd.com/read/29068151/cytomegalovirus-retinitis-in-hiv-negative-patients-associated-conditions-clinical-presentation-diagnostic-methods-and-treatment-strategy
#20
REVIEW
Yinon Shapira, Michael Mimouni, Vicktoria Vishnevskia-Dai
In recent years, numerous reports have tied cytomegalovirus retinitis (CMVR) with multiple systemic conditions in the absence of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). These range from reports in apparently healthy individuals, through conditions rendering limited immune dysfunction such as advanced age and diabetes mellitus, and finally severe immune dysfunction such as in haematological and rheumatological conditions. Reports are also emerging, suggesting that induced local ocular immunosuppression is a risk factor for CMVR...
October 25, 2017: Acta Ophthalmologica
keyword
keyword
97091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"